Elevation Wealth Partners
RYTM icon

Elevation Wealth Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Elevation Wealth Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$188K Hold
1,971
– – 0.05% 148
2026
Q2 		$219K Hold
1,971
– – 0.07% 128
2026
Q1 		$171K Hold
1,971
– – 0.06% 125
2025
Q4 		$211K Hold
1,971
– – 0.07% 113
2025
Q3 		$199K Hold
1,971
– – 0.07% 114
2025
Q2 		$125K Hold
1,971
– – 0.05% 151
2025
Q1 		$104K Hold
1,971
– – 0.05% 166
2024
Q4 		$110K Hold
1,971
– – 0.05% 157
2024
Q3 		$103K Hold
1,971
– – 0.04% 161
2024
Q2 		$80.9K Hold
1,971
– – 0.04% 175
2024
Q1 		$85.4K Buy
1,971
+1,571
+393% +$68.8K 0.04% 174
2023
Q4 		$9.17K Buy
+400
New +$12.6K 0.01% 339

Other funds holding RYTM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Cannon Financial Strategists
Cannon Financial Strategists Athens, Georgia $885M AUM 13.17% 1-Year Est. Return
Aspiriant LLC
Aspiriant LLC Los Angeles, California $4.08B AUM 12.02% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Elevation Wealth Partners's RYTM Position: Q3 2026 in Review

Elevation Wealth Partners held its Rhythm Pharmaceuticals (RYTM) position steady in Q3 2026 at 1,971 shares worth $188K. The position accounts for 0.05% of the portfolio, ranked #148.

Elevation Wealth Partners first reported a position in RYTM in Q4 2023 and has held it in 12 quarters since. The position peaked at $219K in Q2 2026. 48 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Elevation Wealth Partners held 1,971 shares of Rhythm Pharmaceuticals worth $188K as of Q3 2026.
  • Elevation Wealth Partners left its Rhythm Pharmaceuticals share count unchanged in Q3 2026.
  • Rhythm Pharmaceuticals made up 0.05% of Elevation Wealth Partners's portfolio in Q3 2026, its #148 holding.
  • Elevation Wealth Partners first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Elevation Wealth Partners's Rhythm Pharmaceuticals position peaked at $219K in Q2 2026.
  • 48 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.